SER-3 News
Most Popular SER-3 Story
Emerging Drug Developers: Serentis
When Tim Sharpington looks across the landscape of biotechnology, it’s easy for him to find examples of the kind of company he’d most like to emulate. The UK’s
Latest Headlines
- August 23, 2007
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
